Back to Search Start Over

Seal Rock Therapeutics to Present Preclinical Efficacy Findings for SRT-015 in Cholestatic Liver Diseases at the European Association for Study of the Liver (EASL) Congress 2024

Source :
PR Newswire. May 29, 2024
Publication Year :
2024

Abstract

Abstract selected as TOP abstract for Congress Presentation SEATTLE, May 29, 2024 /PRNewswire/ -- Seal Rock Therapeutics, Inc., a clinical stage company developing first-in-class and best-in-class kinase inhibitors, today announced [...]

Details

Language :
English
Database :
Gale General OneFile
Journal :
PR Newswire
Publication Type :
News
Accession number :
edsgcl.795649997